Furthermore, the EP4 antagonist significantly reduces peritoneal fibrosis and improves dysfunction by inhibiting NLRP3 inflammasome and p-p65-mediated inflammatory responses (67). Here, PTGER4 is linked to Peritoneal Fibrosis.